• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ambrx Biopharma, Inc. - Common Stock (NY:AMAM)

N/A UNCHANGED
Last Price Updated: 7:00 PM EDT, Mar 16, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 10.66 (3)
Ask (Size) 11.24 (1)
Prev. Close 10.13
Today's Range N/A - N/A
52wk Range N/A - N/A
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
3 Dividend Stocks That Are Too Good to Ignore: Q1 Edition ↗
February 26, 2024
Here are the three dividend stocks that will never disappoint you. Buy them while they trade at a discount. 
Via InvestorPlace
News headline image
3 Stocks to Buy That Are Up 200% or More in 2024 ↗
February 23, 2024
Each of these stocks up 200% in 2024 offer unique upside opportunities for investors, including equity arbitrage plays. 
Via InvestorPlace

Performance

More News

Read More
News headline image
The 3 Biotech Stocks That Could Make Your February Unforgettable ↗
February 15, 2024
Via InvestorPlace
News headline image
AMBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ambrx Biopharma, Inc. - AMAM
February 10, 2024
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Looking Into Ambrx Biopharma's Recent Short Interest ↗
January 29, 2024
Via Benzinga
News headline image
Assessing Ambrx Biopharma: Insights From 7 Financial Analysts ↗
January 09, 2024
Via Benzinga
News headline image
Health Care Company Johnson & Johnson Announces Merger With Ambrx Biopharma ↗
January 08, 2024
Via Benzinga
News headline image
Better Growth Stock: UnitedHealth Group vs. Johnson & Johnson ↗
January 27, 2024
Via The Motley Fool
News headline image
Johnson & Johnson Secures Complete FDA Approval For Bladder Cancer Drug Balversa, After Almost Five Years Of Accelerated Approval ↗
January 22, 2024
Via Benzinga
News headline image
Johnson & Johnson's Q4 Earnings: Spotlight On Dividend Security Following Kenvue Split, Legal Costs, Acquisitions ↗
January 22, 2024
Via Benzinga
Topics Lawsuit
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)
January 16, 2024
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Week In Review: China Biopharmas Book $9 Billion In Deals During JP Morgan Conference Week ↗
January 13, 2024
Via Talk Markets
News headline image
Stock Market Rally Rebounds; Nvidia, Tesla, JPMorgan, Bitcoin ETFs In Focus: Weekly Review ↗
January 12, 2024
Via Investor's Business Daily
Topics ETFs
News headline image
AMBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ambrx Biopharma, Inc. - AMAM
January 10, 2024
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030
January 09, 2024
Via FinancialNewsMedia
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)
January 08, 2024
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030
January 09, 2024
From FN Media Group LLC
Via GlobeNewswire
News headline image
Dow Surges Over 100 Points; Commercial Metals Posts Upbeat Q1 Results ↗
January 08, 2024
Via Benzinga
Topics Stocks
News headline image
Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
January 08, 2024
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
January 08, 2024
Via Benzinga
News headline image
Crude Oil Falls Sharply; Ambrx Biopharma Shares Spike Higher ↗
January 08, 2024
Via Benzinga
Topics Stocks
News headline image
Why Is Ambrx Biopharma (AMAM) Stock Up 100% Today? ↗
January 08, 2024
Via InvestorPlace
News headline image
Today Is Cancer-Focused Deals Day: Johnson & Johnson Scoops Up Ambrx Biopharma As Merck Boosts Cancer Portfolio With Harpoon Deal ↗
January 08, 2024
Via Benzinga
News headline image
US Stocks Mixed; Nasdaq Jumps Over 100 Points ↗
January 08, 2024
Via Benzinga
Topics Stocks
News headline image
J&J, Merck, Boston Scientific Debut Trio Of Splashy Takeovers Topping $3 Billion In Value ↗
January 08, 2024
Via Investor's Business Daily

Frequently Asked Questions

Is Ambrx Biopharma, Inc. - Common Stock publicly traded?
Yes, Ambrx Biopharma, Inc. - Common Stock is publicly traded.
What exchange does Ambrx Biopharma, Inc. - Common Stock trade on?
Ambrx Biopharma, Inc. - Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Ambrx Biopharma, Inc. - Common Stock?
The ticker symbol for Ambrx Biopharma, Inc. - Common Stock is AMAM on the New York Stock Exchange
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap